Q-omics provides the consensus-scored FAM187B profile across patient tissues and cancer cell-line models. FAM187B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, FAM187B is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, FAM187B RNA expression shows 6,825 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, LUAD, and STAD as cancer lineages where FAM187B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM187B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM187B survival associations across molecular data types. FAM187B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM187B RNA expression–survival associations across cancer types. High FAM187B expression shows unfavorable associations in LUSC and KIRC, but favorable associations in CESC, BLCA, LUAD and ACC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for FAM187B RNA expression.
This table summarizes FAM187B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM187B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM187B shows lower tumor expression in LUAD, LUSC, UCEC, BRCA, THCA and KIRP. The LUAD box plot shows higher FAM187B RNA expression in normal versus tumor tissue (log2 FC = −0.246, t-test p < 0.001).
This table shows molecular features associated with FAM187B in patient tissues and cancer cell lines. In patient samples, FAM187B shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM187B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and STOMACH.
